It's marketed as a generic option to name-brand mood meds, but it's been recalled for the same reason a competitor was just ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

A new study has found that adults with depression who start treatment with newer antipsychotic medications may face a higher ...

Genetic testing is transforming depression treatment by tailoring antidepressants to your DNA for better results and fewer side effects.

Sooma announced that it received FDA investigational device exemption (IDE) for its transcranial direct current stimulation ...

A depression drug candidate that’s a key part of Johnson & Johnson’s neuroscience strategy has failed a Phase 3 clinical trial, the latest dose of disappointing news for an emerging class of ...

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a ...

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...

Legislation requiring healthcare professionals assess a woman for postpartum depression made it over the first hurdles last ...